SecBot SecBot
8-K ·Filed Apr 3, 2026

BTMD

biote Corp.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-142147
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

The company's financial performance is stable but not showing growth, with 2026 guidance only marginally above 2025 results. The significant share repurchases suggest management is returning capital rather than investing in growth. Traders should monitor whether the supply chain acquisition translates into margin improvements and whether future guidance shows actual revenue growth.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
BTMD ▲ +21.34% at T+60d
NEUTRAL call +21.34% · α vs SPY +7.87% · entry $1.64 → $1.99
Entry = T+0 close
Apr 3, 2026
via day close
T+1d
-9.15%
call -9.15% · α -9.21%
$1.49
settled 7mo ago
T+5d
+9.15%
call +9.15% · α +5.01%
$1.79
settled 7mo ago
T+20d
+28.66%
call +28.66% · α +19.68%
$2.11
settled 6mo ago
T+60d
+21.34%
call +21.34% · α +7.87%
$1.99
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Biote Corp. disclosed its 2025 financial results and 2026 guidance in an investor presentation, reporting $192.2M in revenue and $53.5M in Adjusted EBITDA. The company also announced share repurchases totaling $51.5M and a strategic acquisition to strengthen its supply chain. While the financials are solid, the forward guidance is only marginally above prior levels, and the share repurchases represent capital allocation rather than fundamental growth improvement.

Key Facts

  • 2025 Revenue: $192.2M
  • 2025 Adjusted EBITDA: $53.5M (27.8% margin)
  • 2026 Revenue Guidance: Above $190M
  • 2026 Adjusted EBITDA Guidance: Above $38M
  • Share repurchases: $51.5M total (Class V and Class A stock)
  • Strategic acquisition strengthens supply chain and enables margin improvement

Financial Impact

Revenue of $192.2M and Adjusted EBITDA of $53.5M in 2025, with 2026 guidance indicating stable but not growing performance. $51.5M in share repurchases reduces share count but does not improve underlying business fundamentals.

revenueepsdilutioncashFlow

Risk Factors

  • Flat revenue guidance suggests limited growth prospects
  • Share repurchases may indicate lack of attractive growth investment opportunities
  • Reliance on non-GAAP metrics (Adjusted EBITDA) for performance reporting

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-142147
Document: d126766d8k.htm0001193125-26-142147
Document: 0001193125-26-142147-index-headers.html0001193125-26-142147
Document: 0001193125-26-142147-index.html0001193125-26-142147
Document: 0001193125-26-142147.txt0001193125-26-142147
4 reports for BTMD
Performance horizon
Filters
Rows
Reports for BTMD — sortable, filterable
TypeNow
Sep 22, 2026
4w ago
Institutional Cluster
NEUTRAL ★ 3/10
$1.32 $1.07▼ −18.94%▼ −18.38%$1.15 (−12.88%)
Sep 18, 2026
5w ago
SC 13G/A
NEUTRAL ★ 4/10
$1.36 $1.09▼ −20.22%▼ −20.43%$1.15 (−15.44%)
Jun 2, 2026
20w ago
8-K
NEUTRAL ★ 4/10
$2.11 $2.17▲ +2.84%▲ +3.84%$1.15 (−45.50%)
Apr 3, 2026
29w ago
8-K
NEUTRAL ★ 4/10
$1.64 $2.11▲ +28.66%▲ +19.68%$1.15 (−29.88%)
Showing 4 of 4

US Market Status

Market Closed — Opens in 3h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026